Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEW PRAGUE, Minn. - Electromed, Inc. (NYSE American: ELMD), known for its innovative airway clearance technologies and maintaining a strong financial health score of "GREAT" according to InvestingPro, is set to be included in the Russell 2000® Index and the Russell 3000® Index after the market closes on June 27, 2025. This move follows the company’s recognition in a preliminary list of additions by FTSE Russell on May 23, 2025. The company has demonstrated solid performance with a 14.85% revenue growth over the last twelve months.
The inclusion in these indices marks a significant milestone for Electromed, reflecting its growth and efforts to enhance shareholder value. The Russell 3000 Index captures the 3,000 largest U.S. stocks, representing about 98% of the investable U.S. equity market, while the Russell 2000 Index focuses on small-cap companies and is a subset of the Russell 3000. With a robust gross profit margin of 77.55% and a healthy current ratio of 5.19, Electromed demonstrates strong operational efficiency.
Jim Cunniff, President and CEO of Electromed, expressed satisfaction with the company’s upcoming inclusion in these prominent indices, noting their importance to institutional investors and their role in index-linked financial products. The Russell US Indexes, which the Russell 2000 and 3000 are part of, are benchmarks for approximately $10.6 trillion in assets.
Electromed’s primary product, the SmartVest® Airway Clearance System, is designed to aid patients with compromised pulmonary function. Established in 1992 and headquartered in New Prague, Minnesota, the company has been committed to improving patient outcomes through its technologies.
This development is based on a press release statement from Electromed, Inc.
In other recent news, Electromed, Inc. announced the approval of a $5 million stock repurchase program by its board of directors. This authorization allows the company to buy back its common stock, although it does not obligate the acquisition of a specific number of shares. The repurchase plan, authorized on March 6, 2025, will be executed at management’s discretion based on market conditions and legal requirements. Electromed may conduct these repurchases through various methods, including open market transactions and privately negotiated deals. Jim Cunniff, President and CEO, noted that the plan demonstrates the company’s confidence in its business and commitment to enhancing shareholder value. Cunniff emphasized using excess cash reserves for stock repurchases as a strategy to return capital to shareholders while maintaining a strong financial position. Electromed is committed to preserving its ability to invest in future growth while executing the repurchase plan. The company has cautioned investors about the forward-looking nature of these plans, which are subject to risks and uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.